Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Docetaxel chemotherapy remains the standard of care in castration-resistant prostate cancer.

Docetaxel chemotherapy remains the standard of care in castration-resistant prostate cancer. Nat Clin Pract Oncol. 2008 Sep; 5(9):506-7.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.